Flibanserin

Drug Profile

Flibanserin

Alternative Names: Addyi; BIMT 17; BIMT 17 BS; Girosa®

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Sprout Pharmaceuticals
  • Class Antidepressants; Anxiolytics; Benzimidazoles; Ketones; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Female sexual dysfunction
  • Discontinued Major depressive disorder

Most Recent Events

  • 19 Oct 2015 Launched for Female sexual dysfunction in USA (PO) - First global launch
  • 18 Aug 2015 Registered for Female sexual dysfunction in USA (PO) - first global approval
  • 04 Jun 2015 The FDA's Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee recommend approval of flibaserin for Hypoactive Sexual Desire Disorder, with a risk management option beyond labelling, in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top